Leukotriene Antagonism in Recruitment of CD49d Expressing Neutrophils in Atopic Subjects

Nasal Allergy Clinical Trial

Official title: Double Blind Study of Leukotriene Antagonism in the Nasal Recruitment of CD49d Expressing Neutrophils in Atopic Subjects

Status Completed

Clinical Trial Summary

The purpose of this study is to see if the recruitment of a certain cell type (the alpha 4 integrin (CD49d) expressing neutrophil) during a nasal allergen challenge can be inhibited by pretreatment with an FDA approved leukotriene antagonist (montelukast).

Clinical Trial Description

Subjects will be consented, undergo skin testing, medical history questionnaires, and randomized to either placebo or montelukast (10 mg). In one week, subjects return, undergo a blood draw, medical history questionnaires, nasal lavage, and nasal allergen challenge (followed by lavage in 6 hours). Subjects will then cross-over to the other study drug. One week later subjects will undergo a blood draw, medical history questionnaires, lavage, allergen challenge, and repeat lavage (after 6 hours). ;

Related Conditions & MeSH terms

• Hypersensitivity
• Nasal Allergy

• NCT number: NCT03039101
• Study type: Interventional
• Source: Nationwide Children's Hospital
• Status: Completed
• Phase: N/A
• Start date: September 6, 2017
• Completion date: July 16, 2018